Small-Angle X-ray Scattering for Pharmaceutical Applications - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Small-Angle X-ray Scattering for Pharmaceutical Applications
The author describes the development of small-angle X-ray scattering and analyzes its advantages in the characterization of drug-delivery systems and large molecules. This article is part of a special Analytical Technology issue.


Pharmaceutical Technology
Volume 34, pp. s32-s37

Technical concepts

The main technical challenges of SAXS are to separate the strong primary X-ray beam from the weak scattering information close to the primary X-ray beam and to increase the intensity of the scattered X-rays.


Figure 2: A typical setup for a small-angle X-ray scattering instrument includes a source, collimation system with optics (i.e., mirror), sample holder, and detector. The area that the beam enters after passing the mirror is typically evacuated to reduce unwanted scattering from gas molecules.
Scientists have used different concepts to achieve these goals. However, all SAXS instruments feature an X-ray source, a collimation system focusing optics, a sample holder, a beam stop, and a detector (see Figure 2).

X-ray sources

To date, copper anodes, producing Cu–Kα radiation, have been the best compromise between sensitivity and absorption. The following three technologies are currently in use:

  • Sealed-tube sources
  • Rotating-anode sources
  • Microfocus sources.

In sealed-tube sources, the electrons are accelerated toward a fixed anode. Part of the energy is emitted as X-rays, but the majority is converted to heat. In sealed-tube sources, the anode is fixed, so a limited amount of energy can be dissipated before the copper melts. Rotating-anode sources exceed this limit and avoid local overheating (5).

Microfocus sources use electromagnetic lenses to focus the electron beam to a fine point, thus producing a high-brilliance X-ray beam.

Scientists typically consider operating costs, energy consumption, and flexibility when choosing an X-ray source. They also must determine whether the source will match with other components of the SAXS system.

X-ray optics and collimation systems




Focusing optics increase the photon flux through the sample. Visible-light lenses and electromagnetic fields such as electron beams cannot focus X-rays. Multilayer mirrors reflect X-rays on a layered surface under the Bragg condition (see Equation 3). Depending on the layers' thickness, a certain wavelength positively interferes (i.e., reflects) at a specific angle (5).

By reflecting certain wavelengths at certain angles, multilayor mirrors can produce monochromatic X-rays. The mirror's curvature produces the desired beam focus, typically parallel or converging.

The monochrome and focused beam then travel through the collimation system to produce a precise beam profile. The following two collimation methods are common:

  • Point collimation (i.e., a pinhole system)
  • Line collimation (i.e., a slit system).

Point-collimation systems send a point-shaped beam through a series of three pinholes. The first two pinholes produce a parallel beam, and the third pinhole blocks unwanted scattering produced by previous pinholes.

Line-collimation systems use a line-shaped beam and employ slits instead of pinholes. The block collimator, a compact and effective design to eliminate parasitic scattering by the collimation system itself, was suggested by Kratky (4).


Figure 3: Scattering patterns of silver behenate. The liquid crystalline structure with clear concentric rings in the case of a point-shaped beam profile (i.e., point collimation) (right) becomes smeared when using a line-shaped beam (i.e., line collimation) (left). The line-collimated experiment yields higher intensity. Reversing the smearing effect requires knowledge of the beam profile and position.
Line collimation increases the photon flux through the sample by replacing a single point-shaped beam with the equivalent of many such points arranged in a line. The increase in intensity comes at the cost of a smearing effect on the scattering image (4). Figure 3 shows the effects of line collimation.

Desmearing data is a mathematical operation that requires knowledge of the beam profile that causes the smearing effect (6–8). New technologies report the beam profile and position so that desmearing becomes a simple and precise routine, thus alleviating earlier concerns (9, 10).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
12%
To select process for new products only
23%
To select processes for both new and legacy products
21%
Do not use QbD
23%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here